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Abstract 23 
The precise control of gene expression by transcription factor networks is critical to 24 
organismal development. The predominant approach for mapping transcription factor-25 
chromatin interactions has been chromatin immunoprecipitation (ChIP). However, ChIP 26 
requires a large number of homogeneous cells and antisera with high specificity. A second 27 
approach, DamID, has the drawback that high levels of Dam methylase are toxic. Here we 28 
modify our Targeted DamID approach (TaDa) to enable cell type-specific expression in 29 
mammalian systems, generating an inducible system (mammalian TaDa or MaTaDa) to 30 
identify protein/DNA interactions in 100 to 1000 times fewer cells than ChIP. We mapped 31 
the binding sites of key pluripotency factors, OCT4 and PRDM14, in mouse embryonic stem 32 
cells, epiblast-like cells and primordial germ cell-like cells (PGCLCs). PGCLCs are an 33 
important system to elucidate primordial germ cell development in mice. We monitored 34 
PRDM14 binding during the specification of PGCLCs, identifying direct targets of PRDM14 35 
that are key to understanding its critical role in PGCLC development. We show that MaTaDa 36 
is a sensitive and accurate method to assess cell type specific transcription factor binding in 37 
limited numbers of cells.  38 
  39 
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Introduction 40 
Chromatin immunoprecipitation (ChIP) has been widely used to characterise transcription 41 
factor-chromatin interactions (Furey, 2012), but this approach is limited by the requirement 42 
for large numbers of  homogeneous cell populations and specific antibodies (Tsankov et al., 43 
2015). As a result, mapping transcription-factor occupancy in vivo in rare cell types, such as 44 
stem cells, is technically challenging. DNA adenine methylation identification (DamID) has 45 
recently emerged as an alternative approach for genome-wide profiling (Aughey and 46 
Southall, 2016; Marshall and Brand, 2015; Marshall et al., 2016; Otsuki et al., 2014; Southall 47 
et al., 2013; van Steensel and Henikoff, 2000). In DamID, a DNA- or chromatin-binding 48 
protein is fused to an E. coli Dam methylase. Wherever the Dam-fusion protein binds to 49 
DNA or chromatin, it methylates adenine within the sequence GATC. Endogenous adenine 50 
methylation is extremely rare in eukaryotes (Koziol et al., 2015; Wu et al., 2016; Zhang et al., 51 
2015) such that the tagged sequences can be detected easily by digestion with DpnI, which 52 
only cuts at methylated GATC sites. In this way binding sites can be identified genome-wide 53 
without cell isolation, fixation or immunoprecipitation.  54 
Although DamID is particularly well suited for in vivo analysis, a major caveat is cytotoxicity 55 
resulting from high levels of expression of the Dam methylase (Southall et al., 2013; 56 
Catherine Davidson and A.H.B., data not shown ). As a result, DamID in mammalian cells 57 
has generally relied on low level, ubiquitous expression from an uninduced heat-shock 58 
promoter (van Steensel and Henikoff, 2000; Vogel et al., 2007). However, this precludes the 59 
identification of cell-type-specific binding or detection of dynamic changes in DNA- or 60 
chromatin-interactions. To overcome these limitations, we modified Targeted DamID (TaDa) 61 
(Southall et al., 2013) for use in mammalian cells, enabling the rapid, accurate and sensitive 62 
identification of transcription factor binding sites. Mammalian TaDa (MaTaDa) enables 63 
genome-wide protein-DNA interaction profiling in a temporally regulated, cell type-specific 64 
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fashion.  65 
First, we validated MaTaDa in murine embryonic stem cells by reanalysing OCT4 occupancy 66 
during the transition from the naϊve to primed pluripotent cell state (Buecker et al., 2014) 67 
Next, we mapped the binding sites of the transcription factor PRDM14, which controls 68 
embryonic stem cell (ESC) pluripotency and is of pivotal importance for acquisition of 69 
primordial germ cell (PGC) fate in mice . Making use of in vitro specification of PGC-like 70 
cells (PGCLCs), we identified a set of novel cis-regulatory elements bound by PRDM14 71 
specifically in PGCLCs. Analysis of these loci suggests that PRDM14 is involved in the 72 
suppression of EGFR/MAPK signalling and the regulation of genes associated with cell 73 
migration.   74 
A mammalian system for Targeted DamID 75 
We engineered a construct for conditional expression of Dam-fusion proteins in mammalian 76 
cells, comprising a ubiquitous promoter (PGK) driving expression of a transcript encoding a 77 
primary open reading frame encoding mCherry (ORF1 246 amino acids). The primary ORF 78 
is followed by two TAA stop codons and a single nucleotide frameshift upstream of a 79 
secondary open reading frame encoding the Dam fusion protein (ORF2; Fig 1A). We showed 80 
previously that translation of this bicistronic mRNA results in expression of ORF1 followed 81 
by rare ribosomal re-entry and translational re-initiation, resulting in extremely low levels of 82 
expression of ORF2, the Dam fusion protein (Southall et al., 2013).  83 
For spatial and temporal control of MaTaDa, we inserted a GFP or puromycin coding 84 
sequence and SV40 terminator, flanked by loxP sites, between the PGK promoter and the 85 
TaDa construct (Fig 1A, Fig S2A). To excise the floxed cassette, we used a Cre-estrogen-86 
receptor fusion (Cre-ER) (Fig 1A, Fig S2A). Cre-ER is constitutively expressed, but only 87 
translocates to the nucleus and induces Dam expression upon tamoxifen administration (Fig 88 
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1B, C). In the absence of Cre, GFP or puromycin are expressed and transcription is 89 
terminated upstream of ORF1. The expression of GFP or puromycin can be used to assess 90 
transfection efficiency or select transfected cells. Excision of the stop-cassette results in loss 91 
of GFP or puromycin expression and induction of TaDa. In this way, MaTaDa enables both 92 
spatial and temporal control, directed by targeted expression of Cre, in either cell lines or 93 
transgenic animals. The low levels of Dam methylase expression are non-toxic and preclude 94 
dominant effects that might result from the overexpression of transcription factors. To lessen 95 
the potential for steric effects between the Dam methylase and fused proteins (Ramialison et 96 
al., 2017) we inserted a myc tag as a spacer. 97 
Mapping  binding sites of pluripotency factors with MaTaDa 98 
During early mammalian development pluripotent stem cells have the potential to form all 99 
cell types of the embryo. Naïve and primed pluripotent states have been characterised in 100 
mouse based on the functional, transcriptional and epigenetic characteristics of the pre- and 101 
post-implantation epiblast (Nichols and Smith, 2009). Mouse embryonic stem cells (mESCs) 102 
are used extensively as an in vitro model to study the molecular mechanisms of pluripotency. 103 
In the presence of small molecules that promote Wnt/β-catenin and inhibit FGF/MAPK 104 
signalling mESCs remain in a naïve pluripotent state similar to the pre-implantation epiblast 105 
(Ying et al., 2008) (Fig S1A). Stimulation of the FGF signalling pathway promotes 106 
differentiation of ESCs into epiblast like cells (EpiLCs), a primed pluripotency state. The 107 
unifying mechanistic features of pluripotency are key transcription factors like OCT4 108 
(POU5F1) and PRDM14. OCT4 is a master regulator of both primed and naïve pluripotency 109 
in ESCs (Zeineddine et al., 2014). During the transition from naïve to primed pluripotency, 110 
the OCT4 binding pattern changes dynamically due to the availability of cofactors (Buecker 111 
et al., 2014). PRDM14, which can function as a transcriptional repressor (Nady et al., 2015; 112 
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Yamaji et al., 2013) promotes naïve pluripotency in mESCs (Ma et al., 2011; Yamaji et al., 113 
2013). PRDM14 is also critical for the development of primordial germ cells (Yamaji et al., 114 
2008). 115 
To assess whether MaTaDa can detect differential binding of transcription factors we 116 
generated stable mESC lines carrying MaTaDa constructs encoding either Dam alone or a 117 
Dam-transcription factor fusion protein, together with the CreER-expression construct with a 118 
Zeocine resistance gene (Fig 1A, Fig S2A). Cells were selected for GFP expression or 119 
puromycin resistance  and co-selected with Zeocine and expanded. Induction of CreER with 120 
tamoxifen for 24 hours resulted in induction of Dam expression and the loss of GFP 121 
fluorescence from virtually all cells (97.7%) 48 hours later (Fig 1D,E). Robust methylation of 122 
genomic DNA was detected in treated cells as compared to untransfected or EtOH-treated 123 
cells (Fig 1F). Some faint DNA amplification was observed in cells treated with EtOH (Fig 124 
1F), possibly due to low level expression before tamoxifen treatment and high sensitivity of 125 
the DamID technique. However, the considerably higher induction upon tamoxifen treatment 126 
allowed us to identify changes in transcription factor binding patterns during differentiation.  127 
Importantly, tamoxifen treatment of OCT4-Dam or PRDM14-DAM expressing ESCs did not 128 
lead to a large increase in OCT4 or PRDM14 expression and consequently there was no 129 
effect on pluripotency or differentiation (Fig S1B, Fig S2C).  130 
MaTaDa identifies genome-wide transcription factor occupancy with high accuracy and 131 
sensitivity 132 
We sequenced DamID libraries from 150,000 mESCs expressing either Dam alone (control), 133 
Dam-OCT4 or Dam-PRDM14. OCT4 bound to 18,103 sites, and PRDM14 to 8784 sites 134 
when a cut-off of q<10-25 was used (Fig S3). MaTaDa peaks were consistently detected 135 
between biological replicates (Fig S3A-D), and genome-wide correlations between replicate 136 
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experiments are shown in Fig S3E,F. We detected binding to key OCT4 targets, such as 137 
Nanog, Sox2, Klf4 and Myc (Fig 2A). Similarly, PRDM14 was found to bind key genes 138 
involved in pluripotency, including OCT4 and Nanog, and differentiation, such as Fgfr1 and 139 
Xist (Fig S4A).  140 
Next we compared our data for OCT4 and PRDM14 binding in 150,000 mESCs to published 141 
ChIP-seq data from 50 and 20 million mESCs, respectively (Buecker et al., 2014; Ma et al., 142 
2011). Importantly, due to the nature of DamID in acquiring counts only at GATC-motifs in 143 
the genome, the resolution of signal across the genome is different from ChIP-seq. In 144 
addition, random methylation requires stringent normalization to the Dam-only control, and a 145 
ratio is calculated between Dam-fusion and Dam only. This prevents direct comparisons 146 
between MaTaDa and ChIP-seq in a quantitative manner. We therefore used a peak-centered 147 
analysis for genome-wide comparisons between both techniques. Both the OCT4 and 148 
PRDM14 MaTaDa signals were highly enriched over ChIP peaks (Fig 2B, Fig S4B). 149 
Conversely ChIP-seq signal is highly enriched over MaTaDa peaks (Fig 2C, Fig S4C). 150 
Overlap between peaks was dependent on the stringency of peak calling (Fig 2D-G, Fig 151 
S4D-F), but at q<10-25, 1901 of 3880 (49%) OCT4 ChIP peaks  overlapped with MaTaDa 152 
peaks (18096 peaks at q<10-25) (Fig 2B-G, Fig S5A-C), as did 1824 of 5681(32%) of 153 
PRDM14 ChIP-seq peaks (8784 MaTaDa peaks at q<10-25) (Fig S4B-J) (Ma et al., 2011). 154 
Nevertheless, at any given q-value, a subset of peaks was always specific to either technique 155 
(Fig 2F-G, Fig S4E-F, Fig S5A-E). Interestingly, while both for ChIP-seq and for DamID it 156 
is generally thought that peak intensity grossly correlates with binding strength, the 157 
correlation (R2) for peak intensity of peaks common to both techniques (at q<10-25) was only 158 
0.07 for OCT4 and 0.12 for PRDM14 (Fig 2H, Fig S4H).   159 
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We next conducted motif and genomic feature enrichment analysis (Imrichová et al., 2015) 160 
on the OCT4 MaTaDa peaks (q<10-25). The three most highly ranked transcription factor 161 
motifs for which a position weight matrix was available all corresponded to OCT4-related 162 
motifs (Fig 2I). Interestingly, presence of OCT4-motifs at any given q-value was higher 163 
under common and ChIP-specific than under MaTaDa-specific peaks (Fig S5F). This could 164 
suggest that MaTaDa captures more indirect OCT4 binding events than ChIP-seq in these 165 
conditions. Peaks were also enriched for enhancers and active chromatin, as illustrated by the 166 
enrichment for ESC DNAse-accessible sites and H3K27ac and H3K4me1 histone marks (Fig 167 
2J). The enrichment for genomic features did not change considerably when either MaTaDa 168 
or ChIP-seq specific peaks were analyzed (Fig S5G,H).  169 
We conclude that MaTaDa was able to profile genome-wide transcription factor occupancy 170 
accurately and with high sensitivity, and can function as an alternative or complementary 171 
approach to ChIP-seq. 172 
MaTaDa is sufficiently sensitive to profile rare populations of cells 173 
A major advantage of TaDa over ChIP is the ability to profile rare populations of cells in vivo 174 
(Otsuki et al., 2014; Southall et al., 2013). To test the sensitivity of MaTaDa, we tested 175 
whether MaTaDa could profile binding in only 10,000 cells. Remarkably, the binding profiles 176 
for PRDM14 were strikingly similar to those obtained from 150,000 cells (Fig 3A-C). 177 
However, peak-calling at any given q-value always resulted in more peaks being called from 178 
10,000 than 150,000 cells (Fig 3B-E,G), due to a lower signal-to-noise ratio, as expected 179 
from the low cell number. Nevertheless, the sensitivity of this low-cell number MaTaDa was 180 
very high, with nearly all peaks from 150,000 cells (q<10-100) eventually being recovered by 181 
PRDM14 MaTaDa on 10,000 cells (Fig 3F). The ability to profile transcription factor 182 
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binding in small numbers of cells suggests that MaTaDa has sufficient sensitivity to uncover 183 
transcription factor-genome interactions in rare cell types in vivo.  184 
MaTaDa captures cell-type specific transcription factor binding  185 
We tested whether MaTaDa could profile differential transcription factor occupancy between 186 
different but related cell types by generating OCT4 binding profiles during ESC 187 
differentiation. Removal of 2i and LIF and addition of FGF2 and Activin drives the transition 188 
of naïve ESCs to epiblast-like stem cells (EpiLCs) (Hayashi et al., 2011). EpiLCs are 189 
analogous to the cells of the post-implantation epiblast and are in a primed pluripotent state.  190 
During the transition from ESCs to EpiLCs, OCT4 interacts with OTX2, and together they 191 
bind a distinct set of enhancers to promote the activation of pro-differentiation genes 192 
(Buecker et al., 2014).  193 
First, we generated genome-wide MaTaDa profiles of OCT4 occupancy in naïve ESCs and 194 
EpiLCs (Fig 4). Next, we compared our data to a previously defined set of binding sites that 195 
are bound by OCT4 predominantly in either naïve ESCs or EpiLCs (Buecker et al., 2014). 196 
We found that ground-state pluripotency genes, such as Klf4 (Fig 4A), were bound primarily 197 
in ESCs while pro-differentiation genes, such as Fgf5 (Fig 4B), were bound exclusively in 198 
EpiLCs, but not in the ESCs from which they were derived. Critically, ESC-specific 199 
enhancers were not strongly bound following differentiation (Fig 4C), demonstrating that 200 
MaTaDa is able to capture differential transcription factor occupancy, enabling the detection 201 
of spatially and temporally restricted protein-chromatin interactions.  202 
PRDM14 binding in ESCs and PGCLCs 203 
In addition to controlling ESC pluripotency, PRDM14 is essential for specifying PGCs from 204 
post-implantation epiblast cells (Yamaji et al., 2013). Paralleling mouse embryonic 205 
development, the establishment of a primed pluripotent state in EpiLCs is required for  206 
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specification of  PGCLCs in vitro (Hayashi et al., 2011; Ohinata et al., 2009). Notably, 207 
PGCLCs are functionally equivalent to the PGCs found in the early mouse embryo and hence 208 
represent an important system for studying mammalian germ line development (Hayashi et 209 
al., 2011). PGC identity is controlled by a transcription factor network consisting of BLIMP1, 210 
PRDM14 and TFAp2c, which suppresses expression of somatic genes and promotes 211 
transcription of germ cell genes (Magnúsdóttir et al., 2013; Nakaki et al., 2013). Expression 212 
of PRDM14 was shown to be sufficient to drive differentiation of EpiLCs into PGCLCs 213 
(Nakaki et al., 2013). However, deriving sufficient quantities of PGCLCs is difficult and has 214 
limited the mechanistic understanding of this pivotal developmental process. In particular, it 215 
has not been possible to determine how PRDM14 binding changes during PGCLC 216 
development and the key PRDM14 targets that drive the EpiLC-PGCLC transformation have 217 
not been identified previously.   218 
We induced differentiation of EpiLCs into PGCLs using the growth factors BMP4, BMP8, 219 
SCF, EGF and LIF. PGCLCs (~10-15% of all cells, up to 150,000 per replicate) were then 220 
FACS-purified using endogenous Dppa3-GFP and Esg1-tdTomato reporters (Materials and 221 
Methods, Fig S6). Using MaTaDa we monitored PRDM14 binding in the first 3 days of 222 
PGCLC specification (Fig S6A-D) and found genome-wide changes in PRDM14 binding 223 
(Figure 5A-C). While 77% of binding sites (q<10-100) were shared between ESCs and 224 
PGCLCs, the level of PRDM14 occupancy was strikingly different. 2450 sites were 225 
preferentially bound by PRDM14 in ESCs (>2 fold higher in ESCs) and 698 in PGCLCs (>2 226 
fold higher in PGCLC), suggesting that PRDM14 regulates a functionally distinct set of 227 
genes in ESCs and PGCLCs (Fig 5C). Most PRDM14 peaks occur >2kb from transcriptional 228 
start sites (Fig S7A-C) at distinct sites in ESCs and PGCLCs (Fig S7C). Chen et al. (2012) 229 
defined 1277 putative enhancers in ESCs, based upon chromatin marks and transcription 230 
factor occupancy. Interestingly, we found that ESC-enriched PRDM14 sites coincided with 231 
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these presumptive regulatory regions, but PGCLC-enriched sites did not (Fig 5D). The 232 
PGCLC-enriched sites were enriched for the PRDM14 core motif (GGTCTCTAA; p=4.39e-233 
6). Interestingly, by de novo analysis we discovered another motif (Fig S7E; E=2.1e-033) 234 
that is similar to motifs recognised by RXRG (E=4.80e-05), the pluripotency factors NR5A2 235 
(E=1.52e-4) and NR6A1 (E=4.16e-02) indicating that PGCLC-enriched sites may be 236 
regulatory regions bound by several pluripotency associated factors. A second motif (Fig 237 
S7E; E=2.0e-002) similar to the SOX motif is present at all 698 binding sites. Although SOX 238 
proteins have been shown to recognize similar motifs, they become restricted in their binding 239 
patterns through interactions with specific co-factors (Hou et al., 2017; Kondoh and 240 
Kamachi, 2010). Our data suggest that PRDM14 binds at novel, previously unidentified, 241 
PGCLC-specific enhancers.  242 
Next we analysed genes associated with PRDM14 binding in ESCs and PGCLCs. We found 243 
that ESC-enriched PRDM14 target genes are implicated in the regulation of embryonic 244 
development and negative regulation of cell differentiation  (Fig S7D) which  includes genes 245 
differentially expressed in PRDM14 mutants, like Fgfr1, Fgfr2 and Dnmt3b (Costello et al., 246 
2011; Grabole et al., 2013).  247 
By comparing the transcriptomes of EpiLCs and PGCLCs (Sasaki et al., 2015), we found that 248 
445/2889 differentially expressed genes (15%) are direct targets of PRDM14 (p<1e-16, Fig 249 
5E-F). Key PGC specification genes including Tfap2c, Dppa3, Nr5a2 and Esrrb were both 250 
bound by PRDM14 and upregulated in PGCLCs, while EpiLC genes including Wnt8a, Otx2, 251 
Pou3f1 and Dnmt3a were downregulated. PRDM14 may thus play a key role in PGC 252 
specification by upregulating key reprogramming genes and repressing EpiLC genes. 253 
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PGCLC-enriched PRDM14 targets also included genes involved in EGFR and MAPK 254 
signalling (Fig S7D). Notably, inhibition of the MAPK pathway is sufficient to upregulate 255 
key PGC markers context dependently (Kimura et al., 2014).  256 
Most intriguingly, in both ESCs and PGCLCs PRDM14 binding is enriched in the vicinity of 257 
genes that function in neuronal development, cell migration and cell morphology (Fig S7D). 258 
Consistent with this finding, genes involved in neurogenesis become induced upon depletion 259 
of PRDM14 in ESCs (Yamaji et al., 2013). In the developing mouse embryo PGCs migrate 260 
from the area of specification into the endoderm epithelium of hindgut and colonize the 261 
developing genital ridge at E10.5 (Anderson et al., 2000; Clark and Eddy, 1975). To 262 
investigate a potential function of PRDM14 in PGC migration we focused on Wnt5a and Tnc, 263 
which are significantly bound by PRDM14 in PGCLCs (Fig 5A, Fig S8A) and have been 264 
implicated in cell migration (Chawengsaksophak et al., 2012; Nishio et al., 2005). Expression 265 
of these genes is extremely low in ESCs and EpiLCs (Fig S8B, C). Upon PGCLC induction, 266 
Wnt5a and Tnc expression become induced only in those cells that fail to acquire the PGC 267 
identity, while PRDM14-expressing PGCLCs (Fig S7D) repress both migration associated 268 
genes. In contrast, the Wnt5a receptors Ror2 and Fzd5 are not repressed in specified PGCLCs 269 
(Fig S8E-F) (Ishikawa et al., 2001; Niehrs, 2012). Together, our results suggest that 270 
PRDM14 plays a direct role in controlling PGCLC migration towards the genital ridge.  271 
Discussion 272 
The study of genome-wide interactions of transcription factors and chromatin has been 273 
largely dominated by a single biochemical technique, ChIP. ChIP-seq experiments typically 274 
require millions of cells, precluding the identification of transcription factor targets in small 275 
populations of cells, including stem cells in vivo. In addition, the accuracy in detection of 276 
binding sites, as determined by ChIP, is difficult to assess due to the paucity of alternative 277 
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techniques.  Here, we have developed mammalian Targeted DamID (MaTaDa), which 278 
enables transcription factor occupancy to be profiled with high sensitivity in a temporally and 279 
spatially controlled manner. MaTaDa overcomes the potential toxicity associated with 280 
expression of high levels of Dam methylase and avoids potential artefacts caused by 281 
overexpression of a transcription factor. Notably, expression of Dam-PRDM14 in PGCLCs 282 
did not result in adverse effects on cell growth or PGCLC specification efficiency compared 283 
with parental cells or cell lines expressing Dam alone (Fig S2B-D). A key finding is that 284 
MaTaDa can reveal the binding sites of master regulators of pluripotency in as few as 10,000 285 
cells and potentially even fewer. While we used pure cell populations in this study 286 
experiment we have previously shown that given specific transgene expression TaDa profiles 287 
can be generated from a tiny proportion of cells of interest in complex tissues (Southall et al., 288 
2013). This will allow MaTaDa to be applied in vivo to assess chromatin occupancy in rare 289 
and previously inaccessible cell populations.  290 
Despite the overall similarity of binding profiles, MaTaDa and ChIP-seq results differed in 291 
notable ways. Many binding sites were detected using one method but not the other, despite 292 
the use of identical cell lines and culture conditions (Fig 2, FigS4, FigS5). In this respect it 293 
was striking that the degree of overlap between ChIP-seq peaks and peaks obtained by 294 
MaTaDa was similar for OCT4 and PRDM14. This indicates that the incongruities between 295 
MaTaDa and ChIP might derive from fundamental differences between the two techniques. 296 
Distinguishing which approach is a more accurate reflection of the binding of a transcription 297 
factor is not straightforward. Indeed, no studies have thus far systematically analysed the 298 
similarities between alternative methods for determining the genome-wide occupancy of 299 
transcription factors. Although ChIP signals were strongly enriched over MaTaDa peaks (Fig 300 
2 and FigS4), the intensity of peaks did not always correlate (Fig 2H, Fig S4H). An 301 
underlying assumption of ChIP is that regions that are most strongly detected are most 302 
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commonly or strongly bound and are thus “key targets”. However, additional factors 303 
including binding kinetics, steric effects of fusion proteins (Ramialison et al., 2017), 304 
accessibility of antibody-targeted epitopes and amplification, cross-linking or sonication bias 305 
could all affect the observed MaTaDa and ChIP signal intensities (Meyer and Liu, 2014). 306 
MaTaDa and ChIP may therefore represent complementary approaches for understanding 307 
transcription factor-genome interactions. 308 
We designed MaTaDa to take advantage of the large collection of Cre-expressing constructs, 309 
cell-lines and model organisms for targeted expression in vivo. As has been demonstrated in 310 
Drosophila (Cheetham and Brand, 2018; Marshall and Brand, 2017; Southall et al., 2013), 311 
the generation of MaTaDa transgenic animals for key transcription factors, chromatin 312 
complexes and RNA polymerase II will permit the characterisation of the molecular 313 
landscape of gene regulation in almost any cell-type. Analysing the interactions between 314 
transcription factors and enhancers in small and pure populations of stem cells in vivo will be 315 
of vital importance for an increased understanding of the transcriptional control of 316 
development. While we observe some leakiness in vitro (Fig 1F), our system can clearly 317 
identify rearrangements in transcription factor occupancy. 318 
Taking advantage of the high sensitivity of MaTaDa we were able for the first time to 319 
monitor PRDM14-chromatin association during the course of PGCLC specification. 320 
PRDM14 DNA binding in PGCLCs and ESCs differs significantly in location and intensity, 321 
which may be a consequence of cofactor availability or the distinct epigenetic state of each 322 
cell type. While 2i ESCs reside in an epigenetic state characterised by low abundance of 323 
repressive chromatin marks, such as DNA methylation or H3K9me2, PGCLCs are specified 324 
from EpiLCs, which are associated with elevated levels of repressive chromatin 325 
modifications (Leitch et al., 2013; Zylicz et al., 2015). Hence, the epigenetic environment 326 
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established in EpiLCs could potentially restrict PRDM14 binding during early PGCLC 327 
specification. We found that 15% of genes differentially expressed in the transition between 328 
EpiLCs and PGCLCs are direct PRDM14 targets. Interestingly, PRDM14 may function not 329 
only as a repressor but also as an activator, as it was bound at both up- and down-regulated 330 
genes. Interestingly, PGCLC-enriched PRDM14 binding sites did not correspond to predicted 331 
ESC enhancers (Chen et al., 2012) and may identify novel PGCLC-specific enhancers. 332 
Several of these presumptive enhancers regulate components of the MAPK pathway.  In 333 
mice, PGCs are specified in the proximity of cells undergoing mesodermal differentiation. 334 
Consequently, inductive signals like Wnt and BMP that initiate PGC specification in the 335 
postimplantation embryo are also involved in defining the mesoderm linage (Behringer et al., 336 
1999; Winnier et al., 1995). Further, inhibition of the MAPK pathway during mesodermal 337 
differentiation results in the upregulation of PGC marker genes (Kimura et al., 2014). This 338 
suggests that PRDM14 functions during early murine PGC specification by inhibiting the 339 
MAPK signalling pathway and thereby prevents establishment of the mesodermal cell fate. 340 
Interestingly, we find that PRDM14 binds in the vicinity of genes associated with cell 341 
migration (Fig S7D) such as Wnt5a and Tnc, which are most significantly bound by 342 
PRDM14 in PGCLCs (Fig 5A and S8A). Wnt5a and its receptor Ror2 function in PGC 343 
migration. Loss of Wnt5a signalling strongly impairs PGC migration to the genital ridge 344 
(Chawengsaksophak et al., 2012; Laird et al., 2011). Here we find that Wnt5a and Tnc but 345 
not Wnt5a receptors are repressed in PRDM14-expressing PGCLCs, which suggests that 346 
Wnt5a is secreted from somatic cells to promote directed PGC migration, while Wnt5a 347 
repression in PGCs may prevent autocrine stimulation  348 
Ectopic expression of PRDM14 has been linked to several types of cancer, such as lymphatic 349 
leukaemia, lung carcinoma and most prominently breast cancer (Dettman et al., 2011; 350 
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Nishikawa et al., 2007; Taniguchi et al., 2017; Zhang et al., 2013). A comprehensive 351 
understanding of Wnt5a function in breast cancer remains elusive, however there is evidence 352 
that decreased Wnt5a expression in these tumours is associated with a poorer prognosis 353 
(Zeng et al., 2016). Hence, a link between PRMD14, Wnt5a and cell migration might be of 354 
clinical relevance. We conclude that MaTaDa holds great promise for the in vivo analysis of 355 
transcription factor and chromatin protein interactions during development and disease.  356 
  357 
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Materials and Methods 358 
Embryonic stem (ES) cell culture 359 
E14tg2a ES cells were cultured in Serum/ LIF medium for maintenance (Ser/LIF medium: 360 
GMEM (Invitrogen; 21710-025), 10% FBS (Invitrogen 10270-106), 1% Non Essential  361 
Amino Acid  (Invitrogen; 11140), 1mM Sodium Pyruvate (Invitrogen; 1130-070), 2mM L-362 
Glutamine (Invitrogen; 25030-024), 1% Penicillin-Streptomycin( Invitrogen; 15140-22) 0.2% 363 
2-mercaptoethanol (Invitrogen; 21985-023) and 0.1% LIF (obtained from CSCR Cambridge). 364 
Cells were grown on gelatine-coated cell culture dishes (Thermo-Fisher) and passaged by 365 
dissociating to ESC colonies with TrypLE (Invitrogen 12604-021). For experiments ESCs 366 
were grown in 2i/LIF medium (N2B27 medium (R&D), 1 μM PD0325901, 3 μM 367 
CHIR99021 (Stemgent) and 0.1% LIF (obtained from CSCR Cambridge)) on fibronectin-368 
coated dishes (17 μg ml−1; Millipore) for at least 4 passages.  369 
 370 
Induction of Epiblast-like cells (EpiLCs) and primordial germ cell-like cells (PGCLCs) 371 
EpiLCs were induced as described previously (Hayashi et al., 2011). In brief, 2i ESCs were 372 
differentiated into EpilCs by treatment with FGF2 and ActivinA for 40h. Subsequently, 373 
PGCLCs specification was induced by a cytokine cocktail consisting of BMP4 (0.5µg/ml), 374 
BMP8(0.5µg/ml), SCF (0.1µg/ml), EGF (0.05µg/ml) and LIF (1x; made by CSCR 375 
Cambridge)  (Fig S5A). The induction of PGCLC specification by cytokines is inefficient 376 
and hence, FACS purification of successfully specified cells is required. Here, we made use 377 
of a dual reporter ESC line harbouring stable integrations of GFP and tdTomato in the 378 
endogenous Dppa3 and Esg1 loci, respectively (described in Hackett et al. 2017, manuscript 379 
under revision). While expression of Dppa3/GFP is used to identify specifying PGCLCs, high 380 
Esg1/tdTomato expression marks undesired cell types such as ESCs or EpiLCs. 381 
 382 
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piggyBac transposition 383 
2.5ug of PBase, 0.5µg CreER plasmid, 2.5ug of MaTaDa plasmid was diluted in total 50ul of 384 
Gibco® Opti-MEM™ Media. 5 μl of Lipofectamine 2000 (Invitrogen) was diluted in 45μl of 385 
OptiMem and mixed with the plasmid solution and vortexed. The solution was incubated for 386 
10 mins at room temperature and then added to E14 ESCs in culture. The cells were 387 
incubated for 4-6 hrs at 370C, 5%CO2. The media was then changed. Transfection efficiency 388 
usually ranges between 3-30%. Cells were selected with 25µg/ml Zeocine for 7 days after 389 
transfection. 390 
 391 
Flow cytometry  392 
Embryoids were washed with PBS (Gibco), dissociated by incubation in 10 mM tissue 393 
culture grade EDTA (Invitrogen) for 3-5 min at 37°C and subjected to FACS using the Sony 394 
SH800S Cell Sorter. FACS data were analysed using the Flowjo software. 395 
  396 
qRT-PCR 397 
Total RNA was isolated from 20k to 200k cells using the RNeasy Mini Kit (Qiagen) 398 
including on column DNase digest. cDNA was generated using the SuperScript III Reverse 399 
Transcriptase kit (Thermo Fisher Scientific) and 250 ng random primer (Invitrogen) per 400 
reaction. The cDNA was quantified using the SYBR Select Master Mix (Applied 401 
Biosystems) and the QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific). 402 
PCR reaction mix and qPCR program were prepared according to manufacturer's 403 
instructions.   404  405 
MaTaDa constructs 406 
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To clone the maTaDa construct PGK-LGL-Dam, LT3-Dam-Myc was amplified and inserted 407 
into a vector with the PGK promoted driving expression of a floxed GFP cassette using 408 
Gibson assembly (Fig S9A). The OCT4 CDS was amplified from mESC cDNA and inserted 409 
into PGK-LGL-Dam using the restriction enzymes BglII and NotI (Fig S9B). PGK-LPL-Dam 410 
was constructed by replacing the floxed GFP cassette with a puromycin resistance cassette 411 
(Fig S9C). PRDM14 was amplified from mESC cDNA and inserted into PGK-LPL-Dam 412 
with BglII and NotI (Fig S9D). 413 
 414 
DamID-seq 415 
DamID-seq was performed as described previously (Marshall et al., 2016). Briefly, cells were 416 
dissociated with TrypLE, washed and counted. gDNA was extracted using the Qiagen 417 QIAamp® DNA Micro Kit. The DNA was then digested overnight at 370C with DpnI  to cut 418 
methylated GATC sites (New England Biolabs) and purified with a QIAquick® PCR 419 Purification Kit. Adaptors were blunt-end ligated for two hours at 160C using T4 DNA ligase 420 
(New England Biolabs) and heat inactivated at 650C for 20 minutes. The ligated DNA was 421 
then digested with DpnII to cleave any unmethylated GATC sites (New England Biolabs) and 422 
purified with a 1:1 ratio of Seramag beads. Adaptor-ligated fragments were then amplified 423 
with MyTaqTM (Bioline) and PCR purified. The amplified DNA was then sonicated and 424 
digested with AlwI (New England Biolabs) to remove the adaptors, generating diverse DNA 425 
ends. The fragments were then prepared for Illumina sequencing according to the modified 426 
TruSeq protocol described in Marshall et al., 2017. All sequencing was performed as single 427 
end 50 bp reads generated by the Gurdon Institute NGS Core using an Illumina HiSeq 1500. 428 
 429 
Published data acquisition 430 
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sra files were acquired from the Gene Expression Omnibus (Clough and Barrett, 2016) via 431 
wget (v1.17.1). sra-files were converted with fastq-dump (v2.3.5) to fastq-files or abi-dump 432 
(v2.3.5) to csfasta- & qual-files for colorspace data. 433 
 434 
Quality check (QC) 435 
Quality check was performed for all files individually with FastQC (v0.11.4). Residual 436 
adapter sequences and low quality bases were removed with cutadapt (v1.9.1) or TrimGalore 437 
(v0.4.5) when needed. Total and unique reads were summed to assess library size. The 438 
lengths of the reads was determined as additional quality check with awk (v4.1.3). 439 
 440 
damidseq_pipeline 441 
A file of GATC-sites for GRCm38 genome was generated as gff-file with gatc.track.maker.pl 442 
(see: https://github.com/AHBrand-Lab). Analysis of fastq-files from DamID-experiments 443 
was performed with the damidseq pipeline script (Marshall and Brand, 2015) that maps reads 444 
to an indexed bowtie2 genome (i.e., GRCm38), bins into GATC-fragments according to 445 
GATC-sites and normalises reads against a Dam-only control. Binding intensities were 446 
quantile normalised across all replicates (i.e., across all bedgraph-files) for the same 447 
experiment and subsequently averaged. Pearson correlation coefficients and R2 values for 448 
comparisons of individual normalized replicates were calculated between pairs of bedgraph 449 
files in the RStudio environment with base functions (base, v3.4.3; RStudio, v1.1.423). 450 
 451 
ChIP-seq mapping 452 
Reads were mapped to the indexed mouse genome (mm10) with bowtie2 (v2.2.9) (Langmead 453 
and Salzberg, 2012) or optionally to the corresponding masked version including only major 454 
chromosomes to improve data quality. Resultant sam-files were converted to bam-files, 455 
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sorted and indexed with samtools (v1.3.1) (Li et al., 2009). Duplicates were removed with the 456 
MarkDuplicates picard tool (v.1.95) when needed. Total and unique mapped reads were 457 
counted with awk (v4.1.3) and bedtools (v2.25.0) (Quinlan and Hall, 2010).  458 
 459 
Browser tracks and data visualisation 460 
Reads were extended as well as binned and resulting tracks converted with the bamCoverage 461 
deeptools command (v3.0.2). Files were converted into bw-files with awk (v4.1.3) and 462 
bedGraphToBigWig (v4) or to tdf-files with the Integrative Genomic Viewer (IGV) 463 
(Robinson et al., 2011). Data was visualised using IGV, with the midline for MaTaDa ratio 464 
tracks set at 1, and for ChIP-seq at 0. Heatmaps were generated using Seqplots in the RStudio 465 
IDE (v1.12.0; Stempor and Ahringer, 2016). 466 
 467 
ChIP-peak calling and quantification 468 
Sorted bam-files for input (Buecker, C. et al., 2015) or HA-/EGFP-flag samples (Ma, Z. et 469 
al., 2011; Yamaji, M. et al., 2013) were merged with samtools (v1.3.1) to serve as combined 470 
control sample. Broad peaks were called with MACS2 (v2.1.0) for the individual bam-files in 471 
comparison to the combined control sample with the following specifications: --keep-dup all 472 
--bw 300 --qvalue 0.05 --mfold 5 50 --broad --broad-cutoff 0.1. Peaks were called on the 473 
individual bam-files for the experimental samples in comparison to the combined control 474 
sample. The number of significant peaks were read out at sequentially decreasing q-value 475 
(i.e., represented as “-log10(qvalue)” in line with MACS2), peaks in accessory contigs and 476 
mitochondrial genome were filtered out. Residual peaks sorted according to coordinates and 477 
data converted into bed-format. Reads were accumulated over peaks by intersecting bam-file 478 
derived read coordinates with peaks using bedtools (v2.25.0), summing the reads with awk 479 
(v4.1.3) and normalising them for library size and peak length. Data was prepared and plotted 480 
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with tidy tools in the RStudio IDE as violin and scatterplots (i.e., ggplot2, v2.2.1; tibble, 481 
v1.4.2; tidyr, v0.8.0; readr 1.1.1; purr, v0.2.4; dplyr, v0.7.4; stringr, v1.3.0). 482 
 483 
DamID-peak calling 484 
bam-files with extended reads for Dam only generated by the pipeline for every sample were 485 
merged and used as combined control for each individual Dam fusion sample during MACS2 486 
(v2.1.0) peak calling. Additionally, peaks were called for a merged bam-file consisting of all 487 
Dam fusion samples in comparison to the merged bam-file for Dam only in line with peak 488 
calling for ChIP-samples (i.e., merge-vs-merge). 489 
 490 
Consensus peaks 491 
Peaks were defined as reproducible across all replicates at a given q-value, when overlapping 492 
peaks from these biological replicates were consistently identified in more than 50% (Yang et 493 
al., 2014) of all cases (including the merge-vs-merge, e.g., 2 of 3, 3 of 4). Coordinates of 494 
consensus peaks were defined as the maximum area covered by all overlapping peaks which 495 
prevents peak duplication. 496 
 497 
DamID-peak quantification 498 
DamID-binding intensities for identified peaks were aggregated by identifying all GATC-499 
fragments overlapping with the area of the peak, trimming the first and the last fragment to 500 
peak coordinates and summing the weighted scores associated with the fragments. Data was 501 
analysed and visualized in accordance with the corresponding ChIP datasets in RStudio (see  502 
‘ChIP-peak calling and quantification’). 503 
 504 
Common peaks 505 
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Peaks shared amongst ChIP and DamID or between experiments done with the same 506 
technique were identified by intersecting the corresponding peak collections with bedtools 507 
(v2.25.0) intersectBed. Coordinates of common peaks were defined, deduplicated and sorted 508 
similar to the generation of consensus peaks. The extent of overlap between common peaks 509 
was evaluated depending on the q-value, which was either gradually changed for the sets of 510 
peaks from both techniques or by keeping the q-value of one set and changing the other. The 511 
latter allows to evaluate the recovery of peaks in the compared set despite differing 512 
significance. Similarly, the distributions of common and individual peaks were determined by 513 
identifying the closest peak from the compared dataset to the summits of the investigated 514 
peak set dependent on the q-value with the closest tool of the bedtools suite (v2.25.0). These 515 
distributions were plotted as densities of peak numbers dependent on the distance to the 516 
reference peak summits with ggridges (v0.5.0) in RStudio. 517 
 518 
Annotation  519 
Peaks were annotated to overlapping genomic features or nearest gene, respectively, (e.g., for 520 
intergenic/distal peaks) with the ChIPseeker-package (v1.10.3) in the R-environment using 521 
annotations from TxDb.Mmusculus.UCSC.mm10.knownGene (v3.4.0) and gene IDs from 522 
org.Mm.eg.db (v3.4.0). 523 
  524 
RNASeq  525 
cutadapt (v1.9.1) trimmed reads for RNA-seq from EpiLCs and PGCLCs (Sasaki et al., 2015) 526 
were reconverted from fastq- to csfasta- and qual-file formats and Phred+33-scores translated 527 
into numeric Q scores. Reads were aligned and assembled with tophat (v2.0.14) (Kim et al., 528 
2013) which used bowtie1 (v1.1.2) to map colorspace data using --no-coverage-search. 529 
Differentially expressed genes were identified with cufflinks (v2.2.0; i.e.,  --compatible-hits-530 
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norm --no-length-correction --library-type fr-secondstrand --max-mle-iterations 50000), 531 
cuffmerge (v1.0.0) and cuffdiff (v2.2.0;  i.e., --compatible-hits-norm --no-length-correction --532 
library-type fr-secondstrand --max-mle-iterations 50000 --frag-bias-correction --multi-read-533 
correct) (Trapnell et al., 2012). 534 
 535 
Significant genes were filtered by q-value ≤ 0.05 and a fold-change of ≥ 2 (i.e., EpiLC-vs-536 
d4BVSC) and overlapped with the list of annotated peaks associated with intergenic regions 537 
to identify differentially expressed genes associated with putative enhancer peaks. Similar 538 
numbers of genes were randomly sampled without replacement 10000 times for empirically 539 
testing the enrichment of putative enhancer peaks with the associated genes by approximating 540 
a normal distribution. 541 
 542 
Enrichment 543 
Coordinates for promoters, exons, introns, 5’ and 3’UTRs, as well as intergenic regions were 544 
deduced for transcript and exon annotations from biomaRt (v2.30.0). A list of high 545 
probability enhancers were derived from (Chen et al., 2012). Enrichment analysis for ESC- 546 
and PGCLC-specific as well as common peaks sets (i.e., -log10(q-value)≥100, FC≥2) with 547 
gene features and enhancers was performed with gat (v1.2.2) (Heger et al., 2013) using 548 
100.000 sampling iterations and mm10 chromosomes as workspace. Fold enrichment of 549 
genomic features (i.e., enhancers) or log2 fold enrichment (i.e., gene features) for the 550 
associations were displayed together with their respective q-values. 551 
 552 
Motif detection 553 
Motifs were detected de novo using the MEME suite programs MEME and compared to 554 
known motifs using TOMTOM (Bailey et al., 2015). Enrichment of the PRDM14 motif was 555 
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detected using AME (Bailey et al., 2015). Transcription factor motifs and overlap with 556 
chromatin marks as well as DNaseI Hypersensitivity sites in Oct4 peak sets were screened 557 
with i-cisTarget (Imrichova et al., 2015). 558 
 559 
Data availability 560 
Generated datasets were deposited under the GEO accession GSE101971. 561 
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Figure legends 759 
 760 
Figure 1. Conditional expression of Dam-OCT4 in ESCs 761 
(A) The PGK promoter drives expression of a floxed GFP cassette (green). Upon Cre 762 
induction the floxed cassette is excised allowing expression of ORF1 (white; 246 amino 763 
acids). Rare translational re-initiation results in low-level expression of the Dam-OCT4 764 
fusion protein (ORF2; grey/blue). Cre-ER is constitutively expressed and translocates to the 765 
nucleus upon tamoxifen treatment. (B) E14 mESCs transformed with Dam-alone or Dam-766 
OCT4 MaTaDa constructs were treated with tamoxifen or EtOH for 24 hrs and then allowed 767 
to grow for 48hrs. The cells were then processed for DamID-seq and qPCR. (C) Induction of 768 
Dam transcription after tamoxifen treatment compared to EtOH control measured by qPCR. 769 
Error bars represent mean +/- sem. (D) Following tamoxifen treatment MaTaDa containing 770 
ESCs rapidly lose GFP fluorescence. (E) FACS analysis demonstrates the efficient loss of 771 
GFP fluorescence in MaTaDa expressing cells following Cre induction, with some 772 
perdurance of GFP protein at 72 hours resulting in higher levels of fluorescence compared to 773 
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the parental cell line (E14). (F) Amplification of mouse genomic DNA methylated by 774 
MaTaDa after tamoxifen treatment. 775 
 34 
 776 
Figure 2. MaTaDa accurately profiles genome-wide transcription factor occupancy 777 
 35 
(A) Genome browser view of OCT4 binding at the Myc locus (MaTaDa; average of three 778 
replicates) compared to ChIP. MaTaDa data are represented as fold enrichment of Dam-779 
fusion over Dam only; ChIP-seq data are represented as aligned reads. (B,C) OCT4 MaTaDa 780 
(B) and ChIP-seq (C) ESC signal is plotted over a 10kb window either side of the peak 781 
midpoint, for peaks common to MaTaDa and ChIP-seq (top), specific to MaTaDa only 782 
(middle) and specific to ChIP-seq only (bottom) at q<10-25. Above are metaplots of the 783 
MaTaDa (B) and ChIP-seq (C) signal. (D) Schematic to illustrate how peak recovery between 784 
two different datasets can vary depending on the q-value. (E-G) Number (E) or percentage 785 
(F,G) of peaks called upon changing the q-value for peak-detection, either for MaTaDa and 786 
ChIP-seq in parallel (E), or compared to a fixed q-value <10-25 for MaTaDa (F) or ChIP-seq 787 
(G). Common peaks are grey, MaTaDa-specific peaks are orange, ChIP-seq specific peaks 788 
are blue. (H) Scatterplot of peak intensity for peaks (q<10-25) common to OCT4 MaTaDa and 789 
ChIP-seq. PCC, Pearson correlation coefficient. (I,J) Transcription factor motif (I) and 790 
genomic feature (J) enrichment analysis of OCT4 MaTaDa peaks (q<10-25, 18096 peaks). 791 
Position weight matrices (PWM) are shown for the top three enriched motifs for which a 792 
PWM was available. Normalized enrichment score (NES) and percentage of peaks containing 793 
the feature are indicated.  794 
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 795 
Figure 3. MaTaDa has sufficient sensitivity to profile rare cell populations 796 
(A) Genome browser view of PRDM14 occupancy at the Dnmt3b locus from 10,000 (10k) 797 
cells (average of 5 replicates) and 150,000 (150k) cells (average of 3 replicates). Data are 798 
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represented as fold enrichment of Dam-fusion over Dam only. (B,C) PRDM14 MaTaDa 799 
signal from 150,000 ESC (B) and 10,000 ESC (C) is plotted over a 10 kb window either side 800 
of the peak midpoint, for peaks common to 150k and 10k (top), specific to 150k only 801 
(middle) and specific to 10k only (bottom) at q<10-100. Above are metaplots of the 150k (B) 802 
and 10k (C) signal. (D) Schematic to illustrate how peak recovery can vary depending on the 803 
q-value. (E-G) Number (E) or percentage (F,G) of peaks called upon changing the q-value 804 
for peak-detection, either for 150k and 10k ESC in parallel (E), or compared to a fixed q-805 
value <10-100 for 150k (F) or 10k (G). Common peaks are grey, 150k-specific peaks are 806 
green, 10k-specific peaks are blue.  807 
 808 
 809 
Figure 4. Differential binding of OCT4 in ESCs and EpiLCS as identified by MaTaDa  810 
 (A) Genome browser view of the ground state pluripotency gene Klf4, showing OCT4 811 
binding to nearby enhancers in ESCs (average of three replicates) but not EpiLCs (average of 812 
two replicates).  (B) Genome browser view of the pro-differentiation gene Fgf5, showing 813 
OCT4 binding to nearby enhancers in EpiLCs (average of two replicates) but not ESCs 814 
(average of three replicates). (C) Box plot demonstrating that MaTaDa recapitulates the 815 
dynamic binding of OCT4 to EpiLC and ESC specific sites. P-values <1e-5 unpaired, 816 
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unequal variance t test.  817 
 818 
 819 
Figure 5. Distinct chromatin association of PRDM14 in ESCs and PGCLCs  820 
(A,B) Genome browser view of PGCLC-enriched PRDM14 occupancy in ESCs and PGCLCs 821 
(both average of three replicates) at the Tnc (A) and the Tet2 (B) loci. Shared (S), PGCLC-822 
enriched (Pe) and ES-enriched (Ee) sites are shown. (C) PRDM14 bound regions are 823 
subdivided into ESC-enriched (>2 fold), shared in ESCs/PGCLCs, and PGCLC-enriched (>2 824 
fold). (D) Overlap between ESC-defined enhancers and genomic loci occupied by PRDM14 825 
in ESCs (ESC-enriched), PGCLCs (PGCLC-enriched) or both (shared). P-values are 826 
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calculated by Genomic Association Test (Heger et al., 2013). (E) Comparison between genes 827 
differentially expressed during PGCLC specification and genes bound by PRDM14 in 828 
PGCLCs.  Gene expression is plotted in log2 FPKM (fragments per kilobase mapped reads). 829 
(F) A large proportion of PGCLC-PRDM14 targets are differentially expressed between 830 
EpiLCs and PGCLCs. P values are calculated by an empirical test based on a normal 831 
distribution. 832 
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Supplementary Figures 834 
 835 
 836 
 837 
Supplementary Figure 1. MaTaDa does not affect cell fate 838 
(A) ESCs cultures in 2i media remain in a naïve pluripotency. The addition of FGF and 839 
Activin drives differentiation into EpiLCs, a primed pluripotent state. Supplementation with 840 
BMP, SCF, EGF and LIF promotes the transition into primordial germ cells. (B) qPCR of 841 
key marker genes of pluripotency and endodermal fate reveals that OCT4 MaTaDa has no 842 
effect upon cell fate. 843 
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845 
Supplementary Figure 2. Conditional expression of Dam-PRDM14 does not disrupt 846 
cellular behaviour  847 
(A) Cre-ER is constitutively expressed and translocates to the nucleus upon tamoxifen 848 
treatment. The PGK promoter drives expression of a floxed puromycin resistance cassette 849 
(dark blue). Upon Cre induction the floxed cassette is excised allowing expression of ORF1 850 
(246 amino acids). Rare translational re-initiation results in low-level expression of the Dam-851 
PRDM14 fusion protein (ORF2; grey/green). (B) PRDM14 is not overexpressed and Dnmt3b 852 
remains high in EpiLCs following PRDM14 MaTaDa induction.  (C) The expression of key 853 
marker genes and PRDM14 targets in mESCs are unaffected by PRDM14 MaTaDa. (D) 854 
Brightfield microscopy demonstrated that PRDM14 MaTaDa does not impact EpiLC 855 
differentiation. 856 
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 858 
 859 
Supplementary Figure 3. MaTaDa Peaks are reproducible 860 
(A,B) OCT4 (A) and PRDM14 (B) ESC MaTaDa peaks are consistently detected between 861 
biological replicates. Signal is plotted over a 10 kb window either side of the peak midpoint 862 
(q<10-25) for each of the three replicates. (C,D) Metaplots of the three replicates of OCT4 (C) 863 
and PRDM14 (D) ESC MaTaDa signal over a 10kb window on either side of the peak 864 
midpoint. (E,F) Correlation matrix showing R2 values for genome-wide correlation between 865 
OCT4 (E) and PRDM14 (F) ESC MaTaDa replicates.  866 867 
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 868 
 869 
Supplementary figure 4. Correlation between Prdm14 MaTaDa and ChIP-seq in ESC.  870 
(A,B) PRDM14 MaTaDa (A) and ChIP-seq (B) ESC signal is plotted over a 10 kb window 871 
either side of the peak midpoint, for peaks common to MaTaDa and ChIP-seq (top), specific 872 
to MaTaDa only (middle) and specific to ChIP-seq only (bottom) at q<10-25. Above are 873 
metaplots of the MaTaDa (A) and ChIP-seq (B) signal over a 10kb window on either side of 874 
the peak midpoint. (C) Genome browser view of PRDM14 binding at the Xist locus 875 
(MaTaDa; average of three replicates) compared to ChIP. MaTaDa data are represented as 876 
fold enrichment of Dam-fusion over Dam only; ChIP-seq data are represented as aligned 877 
reads. (D-F) Number (D) or percentage (E,F) of peaks called upon changing the q-value for 878 
peak-detection, either for MaTaDa and ChIP-seq in parallel (D), or compared to a fixed q-879 
value <10-25 for MaTaDa (E) or ChIP-seq (F). Common peaks are grey, MaTaDa-specific 880 
peaks are orange, ChIP-seq specific peaks are blue. (G) Scatterplot of peak intensity for 881 
common, MaTaDa-specific and ChIP-seq-specific peaks at q<10-25. (H) Scatterplot of peak 882 
intensity for peaks common to MaTaDa and ChIP-seq at q<10-25. (I,J) Distribution of peak 883 
intensity in PRDM14 MaTaDa (I) and ChIP-seq (J) for common, MaTaDa-specific and 884 
ChIP-seq-specific peaks at q<10-25.  885 
 886 
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 887 
Supplementary Figure 5. Overlap of OCT4 MaTaDa and ChIP peaks in ESC. 888 
(A) Scatterplot of peak intensity for common, MaTaDa-specific and ChIP-seq-specific peaks 889 
at q<10-25. ChIP-seq peaks are from (Buecker et al., 2014). Dashed outline for common peaks 890 
only is presented in Fig 2H. (B,C) Distribution of peak intensity in OCT4 MaTaDa (B) and 891 
ChIP-seq (C) for common, MaTaDa-specific and ChIP-seq-specific peaks at q<10-25. (D,E) 892 
Distribution of peak density of the nearest common and MaTaDa-specific (D) or ChIP-893 
specific (E) peaks relative to OCT4 ESC ChIP (D) or MaTaDa (E) peak summits at variable 894 
q-values. Insets show distribution of the individual peaks respectively at q<10-200 and q<100. 895 
(F) Transcription factor motif enrichment analysis of all available OCT4-motifs in the i-896 
cisTarget database for OCT4 ESC peaks common to MaTaDa and ChIP, or specific to either 897 
technique at three different q-values (q<10-100, top; q<10-25, middle; q<100, bottom). 898 
Normalized enrichment score (NES) and percentage of peaks containing the motif are 899 
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indicated. ND, not determined. (G,H) Genomic feature enrichment analysis of OCT4 900 
MaTaDa-specific (G) or ChIP-specific (H) peaks (q<10-25). Normalized enrichment score 901 
(NES) and percentage of peaks containing the feature are indicated.  902 
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 903 
 904 
Supplementary Figure 6. PGCLCs specify normally in the presence of PRDM14-Dam 905 
(A) Experimental outline; 2i/LIF cultured, Dppa3/GFP, Esg1/tdTomato transgenic ESCs and 906 
harbouring 1.) no additional transgene (parental), 2.) Dam-PRDM14 or, 3.) Dam inducible 907 
transgenes were differentiated into EpiLCs for 40h. During PGCLC specification cell were 908 
treated with either ethanol (EtOH) or tamoxifen (TAM) for 72h. (B) GFP and tdTomato 909 
fluorescence as well as brightfield microscopy images of transgenic PGCLCs cultured in the 910 
presence of ethanol or tamoxifen (scale bar 100µm) (C) FACS plots of the different 911 
transgenic PGCLCs treated with ethanol or tamoxifen during 72h of PGCLC specification. 912 
Sorted PGCLCs (Dppa3 positive) and control cells (negative) are indicated in the panels. (D) 913 
qPCR analysis of PGC (Prdm14, Blimp1), ESC (Klf4) and EpiLC (Dmnt3b) marker genes on 914 
parental, Dam-PRDM14 or Dam transgenic cell FACS purified PGCLCs (Dppa3) and control 915 
cells (neg), treated with tamoxifen or ethanol.    916 
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  917 
 918 
Supplementary Figure 7.  Genome wide analysis of PRDM14 binding 919 
(A) Genomic distribution of PRDM14 peaks. (B) Enrichment of PRDM14 relative to 920 
genomic features (Genomic association test). (C) PGCLC- and ESC-enriched peaks are 921 
associated with distinct sets of genes. (D) Gene ontology terms associated with ESC-922 
enriched, shared and PGCLC-enriched PRDM14 peaks. (E) Two motifs one of which 923 
resembles the NR5A2 motif and the other which is Sox-like were detected de novo by 924 
MEME (Bailey et al., 2015). 925 
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 927 
 928 
Supplementary Figure 8: Gene expression kinetics 929 
(A) Genome browser view of PRDM14 occupancy in ESCs and PGCLCs at the Wnt5a locus 930 
(both average of three replicates). Shared (S) binding site between ESC and PGCLC is 931 
shown. (B-F) Relative gene expression of indicated genes detected by qRT-PCR in 2i/LIF 932 
ESCs, EpiLCs (40h after induction) and at 3 time points of PGCLC development (24h, 72h 933 
and 120h after induction). Gene expression was normalized to Arbp expression. 72h and 120h 934 
PGCLCs were FACS purified using the Dppa3-GFP reporter gene. Dppa3-positive PGCLCs 935 
are depicted in green and Dppa3-negative somatic cells are depicted in black. Biological 936 
replicates (data points) and average gene expression (bar) are shown. (number of biological 937 
replicates: ESCs 3; EpilCs 4; 24h PGCLCs 3; 27h PGCLCs 4; 120h PGCLCs 2) 938 
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 941 
Supplementary Figure 9: MaTaDa Constructs 942 
(A) PGK-LGL-Dam is a conditional vector for establishing stable cell lines that can inducibly 943 
express low levels of Dam methylase. The vector contains PB 3’LTRs that allow integration 944 
into mammalian genomes with the piggyBac transposase. PGK drives the expression of a 945 
floxed GFP cassette. Upon Cre treatment this cassette will be excised allowing transcription 946 
of mCherry (ORF1, LT3) and Dam. ORF1 will be highly translated but the presence of two 947 
stop codons and a single nucleotide frameshift before Dam results in extremely low levels of 948 
Dam expression. (B) PGK-LGL-Dam with OCT4 CDS inserted in the multiple cloning site. 949 
(C) PGK-LPL-Dam, a modification of PGK-LGL-Dam with the GFP cassette replaced with a 950 
puromycin resistance cassette for antibiotic selection. (D) PGK-LPL-Dam with the PRDM14 951 
CDS inserted into the multiple cloning site. 952 
 953 
